CA3078232A1 - Use of p38 inhibitors to reduce expression of dux4 - Google Patents
Use of p38 inhibitors to reduce expression of dux4 Download PDFInfo
- Publication number
- CA3078232A1 CA3078232A1 CA3078232A CA3078232A CA3078232A1 CA 3078232 A1 CA3078232 A1 CA 3078232A1 CA 3078232 A CA3078232 A CA 3078232A CA 3078232 A CA3078232 A CA 3078232A CA 3078232 A1 CA3078232 A1 CA 3078232A1
- Authority
- CA
- Canada
- Prior art keywords
- dux4
- protein
- cell
- expression
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11024—Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568754P | 2017-10-05 | 2017-10-05 | |
| US201762568673P | 2017-10-05 | 2017-10-05 | |
| US62/568,754 | 2017-10-05 | ||
| US62/568,673 | 2017-10-05 | ||
| US201862682565P | 2018-06-08 | 2018-06-08 | |
| US201862682563P | 2018-06-08 | 2018-06-08 | |
| US62/682,563 | 2018-06-08 | ||
| US62/682,565 | 2018-06-08 | ||
| PCT/US2018/054638 WO2019071144A1 (en) | 2017-10-05 | 2018-10-05 | USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3078232A1 true CA3078232A1 (en) | 2019-04-11 |
Family
ID=63963605
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3078232A Pending CA3078232A1 (en) | 2017-10-05 | 2018-10-05 | Use of p38 inhibitors to reduce expression of dux4 |
| CA3128468A Pending CA3128468A1 (en) | 2017-10-05 | 2018-10-05 | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
| CA3127373A Pending CA3127373A1 (en) | 2017-10-05 | 2018-10-05 | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
| CA3077499A Active CA3077499C (en) | 2017-10-05 | 2018-10-05 | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3128468A Pending CA3128468A1 (en) | 2017-10-05 | 2018-10-05 | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
| CA3127373A Pending CA3127373A1 (en) | 2017-10-05 | 2018-10-05 | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
| CA3077499A Active CA3077499C (en) | 2017-10-05 | 2018-10-05 | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
Country Status (28)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2927715T3 (es) * | 2017-10-05 | 2022-11-10 | Fulcrum Therapeutics Inc | Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD |
| US12458668B2 (en) | 2018-02-02 | 2025-11-04 | Fred Hutchinson Cancer Center | Methods for treating facioscapulohumeral muscular dystrophy |
| US12191023B1 (en) | 2018-03-30 | 2025-01-07 | Flagship Pioneering Innovations Vi, Llc | Systems and methods for patient targeted therapy development |
| IL323757A (en) | 2019-03-15 | 2025-12-01 | Fulcrum Therapeutics Inc | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| EP3772513A1 (en) * | 2019-08-09 | 2021-02-10 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Shp2 inhibitors |
| CA3159239A1 (en) * | 2019-11-29 | 2021-06-03 | Pui Leng Loke | Novel compounds for treatment of diseases related to dux4 expression |
| WO2021105474A1 (en) | 2019-11-29 | 2021-06-03 | Facio Intellectual Property B.V. | New compounds for treatment of diseases related to dux4 expression |
| CN111004802A (zh) * | 2019-12-31 | 2020-04-14 | 深圳市疾病预防控制中心(深圳市卫生检验中心、深圳市预防医学研究所) | 特异抑制p38MAPK基因表达的shRNA重组载体构建方法与应用 |
| TW202144572A (zh) | 2020-03-19 | 2021-12-01 | 美商亞維代堤生物科學公司 | 治療臉肩胛肱骨肌肉失養症之組合物及方法 |
| AU2021257213A1 (en) * | 2020-04-17 | 2022-11-03 | Nevada Research & Innovation Corporation | CRISPR-inhibition for facioscapulohumeral muscular dystrophy |
| AU2021342155A1 (en) | 2020-09-11 | 2023-04-13 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use |
| EP4376842A1 (en) * | 2021-07-27 | 2024-06-05 | Fulcrum Therapeutics, Inc. | Treatment of facioscapulohumeral muscular dystrophy with losmapimod |
| EP4401792A4 (en) | 2021-09-16 | 2025-12-03 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY |
| AU2023418987A1 (en) * | 2022-12-30 | 2025-07-03 | Altay Therapeutics, Inc. | 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors |
Family Cites Families (450)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5593992A (en) | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
| US5670527A (en) | 1993-07-16 | 1997-09-23 | Smithkline Beecham Corporation | Pyridyl imidazole compounds and compositions |
| US6369068B1 (en) | 1995-06-07 | 2002-04-09 | Smithkline Beecham Corporation | Amino substituted pyrimidine containing compounds |
| IL118544A (en) | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
| AP9700912A0 (en) | 1996-01-11 | 1997-01-31 | Smithkline Beecham Corp | Novel cycloalkyl substituted imidazoles |
| ZA97175B (en) | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
| EP0883402A4 (en) | 1996-01-11 | 1999-08-11 | Smithkline Beecham Corp | NEW CYCLOALKYL-SUBSTITUTED IMIDAZOLES |
| EP1005343A4 (en) | 1996-03-08 | 2000-06-07 | Smithkline Beecham Corp | USE OF CSAIDS AS ANGIOGENESIS INHIBITORS |
| EP1017980A4 (en) | 1996-03-12 | 2002-09-18 | Smithkline Beecham Corp | METHOD FOR IDENTIFYING PHARMACEUTICALLY ACTIVE COMPOUNDS |
| US6096748A (en) | 1996-03-13 | 2000-08-01 | Smithkline Beecham Corporation | Pyrimidine compounds useful in treating cytokine mediated diseases |
| WO1997035856A1 (en) | 1996-03-25 | 1997-10-02 | Smithkline Beecham Corporation | Novel treatment for cns injuries |
| WO1997035855A1 (en) | 1996-03-25 | 1997-10-02 | Smithkline Beecham Corporation | Novel treatment for cns injuries |
| WO1998007425A1 (en) | 1996-08-21 | 1998-02-26 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| HUP0002842A3 (en) | 1997-04-24 | 2002-01-28 | Ortho Mcneil Pharm Inc | Substituted imidazoles, process for producing them, pharmaceutical compositions containing them, their use and their intermediates |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US20020156104A1 (en) | 1997-06-13 | 2002-10-24 | Jerry L. Adams | Novel pyrazole and pyrazoline substituted compounds |
| JP2002505690A (ja) | 1997-06-19 | 2002-02-19 | スミスクライン・ビーチャム・コーポレイション | 新規なアリールオキシピリミジン置換イミダゾール化合物 |
| US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
| TW517055B (en) | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
| AR016294A1 (es) | 1997-07-02 | 2001-07-04 | Smithkline Beecham Corp | Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| HRP20000209A2 (en) | 1997-10-20 | 2001-04-30 | Hoffmann La Roche | Bicyclic kinase inhibitors |
| JP2002515891A (ja) | 1997-12-19 | 2002-05-28 | スミスクライン・ビーチャム・コーポレイション | 新規なピペリジン含有化合物 |
| US6162613A (en) | 1998-02-18 | 2000-12-19 | Vertex Pharmaceuticals, Inc. | Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases |
| US6316466B1 (en) | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
| PL344004A1 (en) | 1998-05-05 | 2001-09-10 | Hoffmann La Roche | Pyrazole derivatives as p-38 map kinase inhibitors |
| MY132496A (en) | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
| US6867209B1 (en) | 1998-05-22 | 2005-03-15 | Scios, Inc. | Indole-type derivatives as inhibitors of p38 kinase |
| US6340685B1 (en) | 1998-05-22 | 2002-01-22 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| BR9910621A (pt) | 1998-05-22 | 2001-01-30 | Smithkline Beecham Corp | Novos compostos de imidazol 2-alquil substituìdos |
| US6589954B1 (en) | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| US6448257B1 (en) | 1998-05-22 | 2002-09-10 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| EP1080078B1 (en) | 1998-05-22 | 2006-02-01 | Scios Inc. | Heterocyclic compounds and methods to treat cardiac failure and other disorders |
| AU4429799A (en) | 1998-06-12 | 1999-12-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| ES2221426T3 (es) | 1998-08-20 | 2004-12-16 | Smithkline Beecham Corporation | Nuevos compuestos de triazol sustituidos. |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| AU762245B2 (en) | 1998-09-18 | 2003-06-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| WO2000019824A1 (en) | 1998-10-07 | 2000-04-13 | Smithkline Beecham Corporation | Novel treatment for stroke management |
| US6548503B1 (en) | 1998-11-04 | 2003-04-15 | Smithkline Beecham Corporation | Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| IL146105A (en) | 1999-04-23 | 2005-09-25 | Tadeda Pharmaceutical Company | 5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor |
| HUP0201261A3 (en) | 1999-05-21 | 2003-12-29 | Scios Inc Sunnyvale | Indole-type derivatives as inhibitors of p38 kinase and pharmaceutical compositions containing them |
| CA2374737C (en) | 1999-07-09 | 2008-02-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel process for synthesis of heteroaryl-substituted urea compounds |
| US6541477B2 (en) | 1999-08-27 | 2003-04-01 | Scios, Inc. | Inhibitors of p38-a kinase |
| KR20020032591A (ko) | 1999-09-17 | 2002-05-03 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | 라이노바이러스 감염에서의 csaid의 용도 |
| DE60033307T2 (de) | 1999-10-21 | 2007-07-12 | F. Hoffmann-La Roche Ag | Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen als p38-proteinkinase-inhibitoren |
| ATE349447T1 (de) | 1999-10-21 | 2007-01-15 | Hoffmann La Roche | Alkylamino-substituierte bicyclische heterocyclen als p38 protein kinase inhibitoren |
| JP2003514900A (ja) | 1999-11-23 | 2003-04-22 | スミスクライン・ビーチャム・コーポレイション | CSBP/p38キナーゼ阻害剤としての3,4−ジヒドロ−(1H)−キナゾリン−2−オン化合物 |
| WO2001037837A1 (en) | 1999-11-23 | 2001-05-31 | Smithkline Beecham Corporation | 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS |
| DE60023025T2 (de) | 1999-11-23 | 2006-07-13 | Smithkline Beecham Corp. | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren |
| ES2230171T3 (es) | 1999-11-23 | 2005-05-01 | Smithkline Beecham Corporation | Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa. |
| US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| CA2396693A1 (en) | 1999-12-28 | 2001-07-05 | Stephen T. Wrobleski | Cytokine, especially tnf-alpha, inhibitors |
| AU2001241927A1 (en) | 2000-02-28 | 2001-09-12 | Scios Inc. | Inhibitors of p38-alpha kinase |
| AR030053A1 (es) | 2000-03-02 | 2003-08-13 | Smithkline Beecham Corp | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas |
| US6565880B2 (en) | 2000-07-24 | 2003-05-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| KR100571339B1 (ko) | 2000-08-31 | 2006-04-17 | 에프. 호프만-라 로슈 아게 | 세포증식 억제제로서의 7-옥소 피리도피리미딘 |
| JP4146721B2 (ja) | 2000-08-31 | 2008-09-10 | エフ.ホフマン−ラ ロシュ アーゲー | 7−オキソ−ピリドピリミジン類 |
| AU2002248269A1 (en) | 2000-10-19 | 2002-08-12 | Smithkline Beecham Corporation | Use of p38 inhibitors for the treatment of inflammation-enhanced cough |
| EP1337250A2 (en) | 2000-10-19 | 2003-08-27 | SmithKline Beecham Corporation | Use of p38 inhibitors for the treatment of smoke inhalation |
| AU2002246855B2 (en) | 2000-10-23 | 2005-12-22 | Smithkline Beecham Corporation | Novel compounds |
| AU3276002A (en) | 2000-11-17 | 2002-05-27 | Bristol Myers Squibb Co | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| JP2004536779A (ja) | 2000-11-20 | 2004-12-09 | サイオス インコーポレイテッド | p38キナーゼのインドール型阻害剤 |
| DE60125980T2 (de) | 2000-11-20 | 2007-10-25 | Scios Inc., Sunnyvale | P38kinase-inhibitoren vom piperidin/piperazin-typ |
| AU2002226911A1 (en) | 2000-11-20 | 2002-06-03 | Scios Inc. | Indol derivative and their use as inhibitors of p38 kinase |
| US20020165286A1 (en) | 2000-12-08 | 2002-11-07 | Hanne Hedeman | Dermal anti-inflammatory composition |
| JP2004521892A (ja) | 2000-12-20 | 2004-07-22 | メルク エンド カムパニー インコーポレーテッド | (ハロ−ベンゾカルボニル)複素環縮合フェニル系p38キナーゼ阻害剤 |
| SK11322003A3 (en) | 2001-02-12 | 2004-10-05 | Hoffmann La Roche | 6-Substituted pyrido-pyrimidines |
| US6667346B2 (en) | 2001-02-28 | 2003-12-23 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfones |
| WO2002072576A1 (en) | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
| OA12552A (en) | 2001-03-09 | 2006-06-06 | Pfizer Prod Inc | Triazolopyridines as anti-inflammatory agents. |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2002076463A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2002076984A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2002076396A2 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| ATE304009T1 (de) | 2001-04-04 | 2005-09-15 | Pfizer Prod Inc | Neue benzotriazole mit entzündungshemmender wirkung |
| CN1247258C (zh) | 2001-04-24 | 2006-03-29 | 默克专利有限公司 | 使用抗血管生成剂和TNFα的联合疗法 |
| WO2002090360A1 (en) | 2001-05-10 | 2002-11-14 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US7271181B2 (en) | 2001-05-11 | 2007-09-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| SI1397364T1 (sl) | 2001-05-24 | 2007-12-31 | Lilly Co Eli | Novi pirolni derivati kot farmacevtske uäśinkovine |
| WO2002100405A1 (en) | 2001-06-11 | 2002-12-19 | Vertex Pharmaceuticals Incorporated | Isoquinoline inhibitors of p38 |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| AU2002316421B2 (en) | 2001-06-26 | 2008-05-15 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-ALPHA expression |
| ES2284887T3 (es) | 2001-07-11 | 2007-11-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Metodos para tratar enfermedades transmitidas por citocinas. |
| CA2454913A1 (en) | 2001-08-20 | 2003-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin |
| BR0212077A (pt) | 2001-08-30 | 2004-09-28 | Hoffmann La Roche | Compostos de aminopirróis como agentes antiinflamatórios |
| EP1429779A2 (en) | 2001-09-21 | 2004-06-23 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| AU2002329570A1 (en) | 2001-10-12 | 2003-01-30 | Pfizer Products Inc. | Method of monitoring neuroprotective treatment |
| GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124936D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124932D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124931D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| CA2465499A1 (en) | 2001-11-08 | 2003-05-15 | Merck & Co., Inc. | Compositions and methods for treating osteoporosis |
| IL161667A0 (en) | 2001-11-09 | 2004-09-27 | Scios Inc | Method and composition to treat cystic fibrosis |
| US20050261836A1 (en) | 2001-12-05 | 2005-11-24 | Wuyi Meng | Crystal structure of mitogen-activated protein kinase-activated protein kinase 2 and binding pockets thereof |
| AU2002366644A1 (en) | 2001-12-11 | 2003-06-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for administering birb 796 bs |
| US20050202090A1 (en) | 2002-01-03 | 2005-09-15 | Clarke Allan J. | Novel pharmaceutical dosage forms and method for producing same |
| AU2003219656B2 (en) | 2002-01-15 | 2007-05-17 | Merck Sharp & Dohme Corp. | 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators |
| DE10203749A1 (de) | 2002-01-31 | 2003-08-14 | Boehringer Ingelheim Pharma | Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE10203741A1 (de) | 2002-01-31 | 2003-08-14 | Boehringer Ingelheim Pharma | Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE10203753A1 (de) | 2002-01-31 | 2003-08-14 | Boehringer Ingelheim Pharma | Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| WO2003068223A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
| CN100369898C (zh) * | 2002-02-12 | 2008-02-20 | 史密丝克莱恩比彻姆公司 | 用作p38抑制剂的烟酰胺衍生物 |
| KR100714519B1 (ko) | 2002-03-07 | 2007-05-07 | 에프. 호프만-라 로슈 아게 | 이환 피리딘 및 피리미딘 p38 키나아제 억제제 |
| NZ534946A (en) | 2002-03-13 | 2007-05-31 | Merck & Co Inc | Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
| US20040122008A1 (en) | 2002-09-05 | 2004-06-24 | Protter Andrew A. | Treatment of pain by inhibition of p38 MAP kinase |
| AU2003220401A1 (en) | 2002-03-18 | 2003-10-08 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
| US6900208B2 (en) | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| RU2310657C2 (ru) | 2002-04-03 | 2007-11-20 | Ф.Хоффманн-Ля Рош Аг | Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их |
| KR20040101398A (ko) | 2002-04-05 | 2004-12-02 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 점액 과다분비의 치료방법 |
| US20030225089A1 (en) | 2002-04-10 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| DE10216339A1 (de) | 2002-04-13 | 2003-10-23 | Boehringer Ingelheim Pharma | Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| WO2003087394A1 (en) | 2002-04-15 | 2003-10-23 | Glaxo Group Limited | A method of identifying a modudator for a serine/theronine kinase |
| KR20040103972A (ko) | 2002-04-19 | 2004-12-09 | 스미스클라인 비참 코포레이션 | 신규 화합물 |
| PL219736B1 (pl) | 2002-04-23 | 2015-07-31 | Bristol Myers Squibb Co | Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie |
| US7388009B2 (en) | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
| ATE418546T1 (de) | 2002-04-23 | 2009-01-15 | Bristol Myers Squibb Co | Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen |
| WO2003092588A2 (en) | 2002-04-30 | 2003-11-13 | Merck & Co., Inc. | 4-azasteroid derivatives as androgen receptor modulators |
| GB0209891D0 (en) | 2002-04-30 | 2002-06-05 | Glaxo Group Ltd | Novel compounds |
| AU2003229305A1 (en) | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
| TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| US7008958B2 (en) | 2002-05-21 | 2006-03-07 | Bristol-Myers Squibb Company | 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same |
| CA2488567A1 (en) | 2002-06-11 | 2003-12-18 | Merck & Co., Inc. | (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents |
| AU2003245989A1 (en) | 2002-07-09 | 2004-01-23 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
| WO2004010929A2 (en) | 2002-07-25 | 2004-02-05 | Scios, Inc. | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS |
| GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| RU2324695C2 (ru) | 2002-08-06 | 2008-05-20 | Ф.Хоффманн-Ля Рош Аг | 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38 |
| WO2004014870A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
| AU2003256297A1 (en) | 2002-08-09 | 2004-02-25 | Eli Lilly And Company | Benzimidazoles and benzothiazoles as inhibitors of map kinase |
| US20040110755A1 (en) | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
| JP2006500365A (ja) | 2002-08-14 | 2006-01-05 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | p38MAPキナーゼインヒビターを用いた抗凝固及び線維素溶解療法 |
| EP1539121A4 (en) | 2002-08-29 | 2008-08-13 | Scios Inc | METHOD OF REQUESTING OSTEOGENESIS |
| PA8579601A1 (es) | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
| JP2006508914A (ja) | 2002-08-30 | 2006-03-16 | ファイザー・プロダクツ・インク | トリアゾロ−ピリジン製造のための新規な方法および中間体 |
| US7012143B2 (en) | 2002-08-30 | 2006-03-14 | Dombroski Mark A | Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
| US7005523B2 (en) | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
| US7037923B2 (en) | 2002-08-30 | 2006-05-02 | Pfizer, Inc. | Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
| US20040092547A1 (en) | 2002-08-30 | 2004-05-13 | Pfizer Inc | Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
| CA2497408A1 (en) | 2002-09-03 | 2004-03-18 | Sarvajit Chakravarty | Indole-type derivatives as inhibitors of p38 kinase |
| WO2004021979A2 (en) | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
| US7115644B2 (en) | 2002-09-13 | 2006-10-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic compounds |
| WO2004026871A1 (en) | 2002-09-17 | 2004-04-01 | Eli Lilly And Company | Novel pyrazolopyridine derivatves as pharmaceutical agents |
| CN1701069A (zh) | 2002-09-27 | 2005-11-23 | 詹森药业有限公司 | 3,4-二取代吡咯及其在治疗炎性疾病中的应用 |
| WO2004033632A2 (en) | 2002-10-04 | 2004-04-22 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| WO2004032874A2 (en) | 2002-10-09 | 2004-04-22 | Scios Inc. | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE |
| US20050288299A1 (en) | 2002-10-09 | 2005-12-29 | Mavunkel Babu J | Azaindole derivatives as inhibitors of p38 kinase |
| WO2004041277A1 (en) | 2002-11-01 | 2004-05-21 | Merck & Co., Inc. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
| PL377620A1 (pl) | 2002-11-18 | 2006-02-06 | F. Hoffmann-La Roche Ag | Diazynopirymidyny |
| DE10255040A1 (de) | 2002-11-26 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbaminsäureester mit anticholinerger Wirksamkeit |
| AU2003299652A1 (en) | 2002-12-06 | 2004-06-30 | Scios Inc. | Methods for treating diabetes |
| US7105537B2 (en) | 2003-01-28 | 2006-09-12 | Bristol-Myers Squibb Company | 2-substituted cyclic amines as calcium sensing receptor modulators |
| CN1771234A (zh) | 2003-02-05 | 2006-05-10 | 布里斯托尔-迈尔斯斯奎布公司 | 吡咯并三嗪激酶抑制剂的制备方法 |
| CA2755297A1 (en) | 2003-02-10 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
| US7205322B2 (en) | 2003-02-12 | 2007-04-17 | Bristol-Myers Squibb Company | Thiazolidine compounds as calcium sensing receptor modulators |
| EP1601672B1 (en) | 2003-02-14 | 2006-07-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
| CA2515939A1 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Novel compounds |
| UA81453C2 (en) | 2003-02-27 | 2008-01-10 | Pyrazolopyridine derivates | |
| KR101099281B1 (ko) | 2003-03-03 | 2011-12-26 | 어레이 바이오파마 인크. | p38 억제제 및 그의 사용 방법 |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US7030112B2 (en) | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308201D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308186D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| ES2279361T3 (es) | 2003-04-16 | 2007-08-16 | F. Hoffmann-La Roche Ag | Derivados de (6-(fenoxi)-pirido-3,4-dipirimidin-2-il)-amina como inhibidores de p38 kinasa para el tratamiento de estados inflamatorios tal como artritis reumatoide. |
| RU2356896C2 (ru) | 2003-04-16 | 2009-05-27 | Ф.Хоффманн-Ля Рош Аг | Производные хиназолина |
| EP1617840A4 (en) | 2003-05-01 | 2008-08-20 | Bristol Myers Squibb Co | PYRAZOLE AMID COMPOUNDS AS KINASE INHIBITORS |
| GB0320244D0 (en) | 2003-05-06 | 2003-10-01 | Aventis Pharma Inc | Pyrazoles as inhibitors of tumour necrosis factor |
| EP1622567B1 (en) | 2003-05-07 | 2013-07-24 | Merck Sharp & Dohme Corp. | Androgen receptor modulators and methods of use thereof |
| ES2298757T3 (es) | 2003-06-04 | 2008-05-16 | Pfizer Inc. | Derivados de z-amino-piridina como agonistas de adrecorreceptores beta-2. |
| CN1832928B (zh) | 2003-06-26 | 2012-07-04 | 诺瓦提斯公司 | 以5元杂环为基础的p38激酶抑制剂 |
| AU2004255749B2 (en) | 2003-06-30 | 2008-12-18 | Merck Sharp & Dohme Corp. | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
| EP1641535A4 (en) | 2003-06-30 | 2008-05-14 | Merck & Co Inc | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS |
| US20060234931A1 (en) | 2003-07-17 | 2006-10-19 | Biggs William H Iii | Treatment of diseases with kinase inhibitors |
| US20050020587A1 (en) | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
| US7153870B2 (en) | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317484D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| GB0317516D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317482D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| CA2533803A1 (en) | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| GB0318814D0 (en) | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| CL2004002050A1 (es) | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| CN1838958A (zh) | 2003-08-22 | 2006-09-27 | 贝林格尔·英格海姆药物公司 | 治疗慢性阻塞性肺病和肺动脉高血压的方法 |
| US20050053600A1 (en) | 2003-09-09 | 2005-03-10 | Lane Thomas E. | Methods for treating rheumatoid arthritis |
| EP1663228A4 (en) | 2003-09-10 | 2010-10-06 | Merck Sharp & Dohme | 17-heterocyclic 4-azasteroid derivatives as androgen receptor modules |
| SG146624A1 (en) | 2003-09-11 | 2008-10-30 | Kemia Inc | Cytokine inhibitors |
| US7232824B2 (en) | 2003-09-30 | 2007-06-19 | Scios, Inc. | Quinazoline derivatives as medicaments |
| WO2005032551A1 (en) | 2003-09-30 | 2005-04-14 | Scios Inc. | TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE |
| WO2005033072A2 (en) | 2003-09-30 | 2005-04-14 | Scios Inc. | Heterocyclic amides and sulfonamides |
| US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| WO2005047284A1 (en) | 2003-11-13 | 2005-05-26 | F. Hoffmann-La Roche Ag | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones |
| EP1538201A1 (en) | 2003-12-02 | 2005-06-08 | F.Hoffmann-La Roche Ag | Method for the recombinant production and purification of protein kinases |
| AU2004305318A1 (en) | 2003-12-18 | 2005-07-07 | Pfizer Products Inc. | Methods of treating acute inflammation in animals with p38 MAP kinase inhibitors |
| GB0329275D0 (en) | 2003-12-18 | 2004-01-21 | Merck Sharp & Dohme | Therapeutic treatment |
| CA2547837A1 (en) | 2003-12-18 | 2005-07-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Polymorph of birb 796, a p38map kinase inhibitor |
| US20060079461A1 (en) | 2003-12-24 | 2006-04-13 | Scios, Inc. | Treatment of multiple myeloma by inhibition of p38 MAP kinase |
| CA2551524A1 (en) | 2003-12-24 | 2005-07-21 | Scios, Inc. | Treatment of malignant gliomas with tgf-beta inhibitors |
| US20060052390A1 (en) | 2003-12-24 | 2006-03-09 | Scios, Inc. | Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition |
| US20060058296A1 (en) | 2003-12-24 | 2006-03-16 | Scios, Inc. | Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase |
| GB0402138D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402143D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| RU2006131045A (ru) | 2004-01-30 | 2008-03-10 | Мерк Патент ГмбХ (DE) | Производные бисарилмочевины |
| GB0402140D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402137D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| US7863310B2 (en) | 2004-02-03 | 2011-01-04 | Eli Lilly And Company | Kinase inhibitors |
| TWI338004B (en) | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| US7652146B2 (en) | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
| JP2007523929A (ja) | 2004-02-26 | 2007-08-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ベンズイミダゾリル誘導体 |
| KR100844864B1 (ko) | 2004-02-27 | 2008-07-09 | 에프. 호프만-라 로슈 아게 | 헤테로아릴-융합 피라졸로 유도체 |
| KR20060114022A (ko) | 2004-02-27 | 2006-11-03 | 에프. 호프만-라 로슈 아게 | 인다졸 유도체 및 그들을 함유하는 약학 조성물 |
| US20080044439A1 (en) | 2004-03-11 | 2008-02-21 | David Nathaniel E | Compositions and Methods for Preventing and Treating Skin and Hair Conditions |
| EP1574501A1 (en) | 2004-03-11 | 2005-09-14 | Pfizer Limited | Quinolinone derivatives, pharmaceutical compositions containing them and their use |
| EP1577292A1 (en) | 2004-03-17 | 2005-09-21 | Pfizer Limited | Phenylaminoethanol derivatives as beta2 receptor agonists |
| EP1577291A1 (en) | 2004-03-17 | 2005-09-21 | Pfizer Limited | Phenylethanolamine derivatives as beta-2 agonists |
| JP2007534757A (ja) | 2004-04-28 | 2007-11-29 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレーターとしてのフッ素付加4−アザステロイド |
| WO2005110455A2 (en) | 2004-05-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating hepatitis virus infection |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| EP1609789A1 (en) | 2004-06-23 | 2005-12-28 | Eli Lilly And Company | Ureido-pyrazole derivatives and their use as kinase inhibitors |
| SI1761520T1 (sl) | 2004-06-23 | 2008-10-31 | Lilly Co Eli | Inhibitorji kinaze |
| US7253167B2 (en) | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| TW200618803A (en) | 2004-08-12 | 2006-06-16 | Bristol Myers Squibb Co | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
| AU2005273612B2 (en) | 2004-08-12 | 2010-10-14 | Pfizer Inc. | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
| CA2576988A1 (en) | 2004-08-25 | 2006-03-09 | Merck & Co., Inc. | Androgen receptor modulators |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| PE20060493A1 (es) | 2004-10-05 | 2006-09-03 | Smithkline Beecham Corp | Compuestos derivados de bifenil (di o tri) carboxamidas como inhibidores de serina/treonina quinasa p38 |
| MX2007004248A (es) | 2004-10-13 | 2007-06-12 | Merck Patent Gmbh | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. |
| JP4931823B2 (ja) | 2004-10-18 | 2012-05-16 | アムジエン・インコーポレーテツド | チアジアゾール化合物及び使用方法 |
| AU2005310238A1 (en) | 2004-10-29 | 2006-06-08 | Merck Sharp & Dohme Corp. | N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators |
| US20060258582A1 (en) | 2004-11-04 | 2006-11-16 | Scios, Inc. | Method of treating myelodysplastic syndromes |
| WO2006048266A2 (en) | 2004-11-04 | 2006-05-11 | Roche Diagnostics Gmbh | Gene expression profiling of leukemias with mll gene rearrangements |
| GB0425057D0 (en) | 2004-11-12 | 2004-12-15 | Pfizer Ltd | L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide |
| WO2006051373A1 (en) | 2004-11-12 | 2006-05-18 | Pfizer Limited | Compounds for the treatment of diseases |
| JP2008520569A (ja) | 2004-11-16 | 2008-06-19 | メルク エンド カムパニー インコーポレーテッド | 卒中を治療するための(2r)−2−プロピルオクタン酸のプロドラッグ |
| WO2006058023A2 (en) | 2004-11-23 | 2006-06-01 | Merck & Co., Inc. | Treatment of stroke with histamine h3 inverse agonists or histamine h3 antagonists |
| US20060111416A1 (en) | 2004-11-24 | 2006-05-25 | Lane Charlotte A L | Octahydropyrrolo[3,4-C]pyrrole derivatives |
| US20070224662A1 (en) | 2004-12-17 | 2007-09-27 | Jun Luo | Post-translational modification of proteins in cell-free expression systems |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| PE20061155A1 (es) | 2004-12-24 | 2006-12-16 | Boehringer Ingelheim Int | Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas |
| US20060154939A1 (en) | 2004-12-24 | 2006-07-13 | Boehringer Ingelheim International Gmbh | Medicaments for the Treatment or Prevention of Fibrotic Diseases |
| ATE538118T1 (de) | 2004-12-28 | 2012-01-15 | Aska Pharm Co Ltd | Pyrimidinylisoxazolderivat |
| US20060178388A1 (en) | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
| RU2007135955A (ru) | 2005-02-28 | 2009-04-10 | Меркле Гмбх (De) | 2-сульфинил-и 2-сульфонилзамещенные производные имидазола и их применение в качестве ингибиторов цитокина |
| US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| JP2008535822A (ja) | 2005-03-25 | 2008-09-04 | グラクソ グループ リミテッド | 新規化合物 |
| UY29439A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| MY145281A (en) | 2005-03-25 | 2012-01-13 | Glaxo Group Ltd | Novel compounds |
| US20060235020A1 (en) | 2005-04-18 | 2006-10-19 | Soojin Kim | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein |
| EP1883404A4 (en) | 2005-05-11 | 2010-03-31 | Array Biopharma Inc | P38 INHIBITORS AND METHODS OF USE |
| WO2006127678A2 (en) | 2005-05-23 | 2006-11-30 | Smithkline Beecham Corporation | Inhibition of p38 mark for treatment of obesity |
| GB0512429D0 (en) | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
| US20070032506A1 (en) | 2005-07-02 | 2007-02-08 | Peter Giannousis | Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride |
| US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| EP1912945A4 (en) | 2005-08-02 | 2010-06-16 | Merck Sharp & Dohme | N- (PYRIDIN-4-YL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS |
| US7879875B2 (en) | 2005-08-12 | 2011-02-01 | Merk Sharp & Dohme Corp. | P38 kinase inhibiting agents |
| EP1928843A1 (en) | 2005-08-22 | 2008-06-11 | Amgen, Inc | Bis-aryl urea compounds for the treatment of protein kinase-mediated diseaes |
| MX2008002590A (es) | 2005-08-25 | 2008-03-18 | Hoffmann La Roche | Inhibidores de la p38-map-cinasa y metodos para el uso de los mismos. |
| EP1919913A2 (en) | 2005-08-25 | 2008-05-14 | F.Hoffmann-La Roche Ag | P38 map kinase inhibitors and methods for using the same |
| KR101011958B1 (ko) | 2005-08-25 | 2011-01-31 | 에프. 호프만-라 로슈 아게 | p38 MAP 키나아제 저해제로서의 융합형 피라졸 |
| CN101243051A (zh) | 2005-08-25 | 2008-08-13 | 霍夫曼-拉罗奇有限公司 | p38 MAP激酶抑制剂及使用它的方法 |
| JP2009506007A (ja) | 2005-08-25 | 2009-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | p38MAPキナーゼ阻害剤及びその使用方法 |
| TW200745034A (en) | 2005-09-01 | 2007-12-16 | Astellas Pharma Inc | New compounds |
| NZ566023A (en) | 2005-09-21 | 2010-02-26 | Pfizer Ltd | Carboxamide derivatives as muscarinic receptor antagonists |
| EP1940407B1 (en) | 2005-09-26 | 2010-11-10 | Merck Sharp & Dohme Corp. | N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamides as androgen receptor modulators |
| WO2007045989A1 (en) | 2005-10-20 | 2007-04-26 | Pfizer Limited | Pyridyl derivatives useful as h3 ligands |
| DOP2006000233A (es) | 2005-10-28 | 2007-06-15 | Lilly Co Eli | Inhibidores de cinasa |
| AR056582A1 (es) | 2005-10-28 | 2007-10-10 | Lilly Co Eli | COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE |
| WO2007056016A2 (en) | 2005-11-02 | 2007-05-18 | Kemia, Inc. | Bisamide cytokine inhibitors |
| JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
| BRPI0618379A2 (pt) | 2005-11-08 | 2011-08-30 | Ranbaxy Lab Ltd | processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico |
| PE20070823A1 (es) | 2005-11-15 | 2007-08-09 | Glaxo Group Ltd | Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona |
| NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| WO2007075896A2 (en) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
| AU2007207743B2 (en) | 2006-01-18 | 2010-07-08 | Amgen Inc. | Thiazole compounds as protein kinase B (PKB) inhibitors |
| WO2007089646A1 (en) | 2006-01-31 | 2007-08-09 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
| EP1984363A1 (en) | 2006-02-09 | 2008-10-29 | Pfizer Limited | Triazolopyridine compounds |
| EP1987022A1 (en) | 2006-02-10 | 2008-11-05 | Pfizer Products Inc. | Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives |
| GB0603684D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| RU2008139625A (ru) | 2006-03-07 | 2010-04-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Композиции и способы лечения ревматоидного артрита |
| AU2007223342A1 (en) | 2006-03-07 | 2007-09-13 | Bristol-Myers Squibb Company | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors |
| AP2402A (en) | 2006-03-20 | 2012-04-30 | Pfizer Ltd | Amine derivatives. |
| WO2007126871A1 (en) | 2006-03-29 | 2007-11-08 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
| CA2649000A1 (en) | 2006-04-12 | 2007-10-18 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases |
| EP2038289A2 (en) | 2006-04-21 | 2009-03-25 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
| EP2035005A4 (en) | 2006-06-09 | 2011-07-06 | Kemia Inc | THERAPY BASED ON CYTOKINE INHIBITORS |
| GB0612026D0 (en) | 2006-06-16 | 2006-07-26 | Smithkline Beecham Corp | New use |
| EP2031965A4 (en) | 2006-06-16 | 2010-06-30 | Glaxo Group Ltd | NEW COMPOUNDS |
| WO2007147103A2 (en) | 2006-06-16 | 2007-12-21 | Glaxo Group Limited | Novel compounds |
| WO2007147109A2 (en) | 2006-06-16 | 2007-12-21 | Glaxo Group Limited | Novel compounds |
| JP5244591B2 (ja) | 2006-06-28 | 2013-07-24 | あすか製薬株式会社 | ピリジルイソオキサゾール誘導体 |
| US20090192164A1 (en) | 2006-06-28 | 2009-07-30 | Aska Pharmaceutical Co., Ltd. | Treating agent of inflammatory bowel disease |
| CA2656507C (en) | 2006-07-17 | 2012-03-20 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| WO2008013823A2 (en) | 2006-07-26 | 2008-01-31 | Scios Inc. | Co-crystals of (2r-trans)-6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n,1-trimethyl-alpha-oxo-1h-indole-3-acetamide |
| JP5275985B2 (ja) | 2006-07-28 | 2013-08-28 | オンコノバ・セラピューティックス・インコーポレーテッド | 放射線保護α,β不飽和アリールスルホン類の処方 |
| PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
| WO2008024391A1 (en) | 2006-08-22 | 2008-02-28 | Scios Inc. | Pharmaceutical formulations of an indole-type derivative and related methods of use |
| KR20090050104A (ko) | 2006-10-04 | 2009-05-19 | 화이자 리미티드 | 아드레날린성 효능제 및 무스카린성 길항제로서 술폰아미드 유도체 |
| EP2086973B1 (en) | 2006-10-11 | 2012-01-25 | Amgen Inc., | Imidazo- and triazolo-pyridine compounds and methods of use therof |
| CA2666769A1 (en) | 2006-10-18 | 2008-04-24 | Merck & Co., Inc. | 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators |
| CA2667543A1 (en) | 2006-10-26 | 2008-05-02 | Boehringer Ingelheim International Gmbh | New pharmaceutical combinations for treatment of respiratory and gastrointestinal disorders |
| US7943617B2 (en) | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| WO2008071664A1 (en) | 2006-12-12 | 2008-06-19 | Smithkline Beecham Corporation | Nicotinamide derivative used as a p38 kinase inhibitor |
| WO2008071665A1 (en) | 2006-12-12 | 2008-06-19 | Smithkline Beecham Corporation | A nicotinamide derivative useful as p38 kinase inhibitor |
| AR064307A1 (es) | 2006-12-13 | 2009-03-25 | Gilead Sciences Inc | Monofosfatos utiles para el tratamiento de la inflamacion pulmonar y broncoconstriccion, formulaciones aerosolicas que los contienen, y metodo de preparacion. |
| KR20090090379A (ko) | 2006-12-13 | 2009-08-25 | 화이자 프로덕츠 인크. | 3-(4-(2,4-디플루오로벤질옥시)-3-브로모-6-메틸-2-옥소피리딘-1(2h)-일)-n,4-디메틸벤즈아미드의 제조 방법 |
| WO2008074676A1 (en) | 2006-12-19 | 2008-06-26 | F. Hoffmann-La Roche Ag | Pyrazolo [3, 4 -d] pyrimidine p38 map kinase inhibitors |
| EP2099779A1 (en) | 2006-12-20 | 2009-09-16 | Brystol-Myers Squibb Company | Crystalline forms of aryl-substituted pyrazole-amide compounds |
| WO2008089034A2 (en) | 2007-01-11 | 2008-07-24 | Kemia, Inc. | Cytokine inhibitors |
| US8063094B2 (en) | 2007-02-08 | 2011-11-22 | Boehringer Ingelheim International Gmbh | Anti-cytokine heterocyclic compounds |
| WO2008103276A2 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| KR101434706B1 (ko) | 2007-02-16 | 2014-08-26 | 아스카 세이야쿠 가부시키가이샤 | 미립자 유성 현탁액을 포함하는 의약 조성물 |
| WO2008104473A2 (en) | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
| SI2125714T1 (sl) | 2007-03-16 | 2011-10-28 | Pfizer Ltd | Hidrokloridna sol 5-(3-(3-hidroksifenoksi)azetidin-1-il)-5-metil-2,2-difenilheksanamida |
| AU2008248073B2 (en) | 2007-05-07 | 2011-03-24 | Amgen Inc. | Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use |
| US8022085B2 (en) | 2007-05-07 | 2011-09-20 | Amgen Inc. | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof |
| US7919504B2 (en) | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
| WO2009015000A1 (en) | 2007-07-25 | 2009-01-29 | Array Biopharma Inc. | Pyrazole urea derivatives used as kinase inhibitors |
| EP2200969A2 (en) | 2007-09-14 | 2010-06-30 | Pfizer Limited | Novel compounds active as muscarinic receptor antagonists |
| US8314131B2 (en) | 2007-09-21 | 2012-11-20 | Amgen Inc. | Triazole fused heteroaryl compounds and methods of use thereof |
| EP2225256B1 (en) | 2007-11-30 | 2013-01-09 | Pfizer Limited | Novel glucocorticoid receptor agonists |
| GB0724258D0 (en) | 2007-12-12 | 2008-01-30 | Glaxo Group Ltd | Novel combinations |
| WO2009074518A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations of prolinamide p2x7 modulators with further therapeutic agents |
| WO2009078992A1 (en) | 2007-12-17 | 2009-06-25 | Amgen Inc. | Linear tricyclic compounds as p38 kinase inhibitors |
| US20110166154A1 (en) | 2008-01-25 | 2011-07-07 | Bristol-Myers Squibb Company | Identification of predictive markers of response to dasatinib in human colon cancer |
| CA2716124A1 (en) | 2008-02-20 | 2009-08-27 | Boehringer Ingelheim International Gmbh | Powder inhalers |
| US8367671B2 (en) | 2008-03-21 | 2013-02-05 | Amgen Inc. | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents |
| JP2009263234A (ja) | 2008-04-21 | 2009-11-12 | Ranbaxy Lab Ltd | ホスホジエステラーゼタイプiv阻害剤の組成物 |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| EP2300466B1 (en) | 2008-06-20 | 2014-08-06 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors |
| WO2009155389A1 (en) | 2008-06-20 | 2009-12-23 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as kinase inhibitors |
| WO2009158446A2 (en) | 2008-06-25 | 2009-12-30 | Bristol-Myers Squibb Company | Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof |
| WO2009158450A1 (en) | 2008-06-25 | 2009-12-30 | Bristol-Myers Squibb Company | Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, preparation and use thereof |
| US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
| PE20110312A1 (es) | 2008-07-15 | 2011-06-25 | Pfizer Ltd | Compuestos piperidinicos de esteres del acido bifenil-2-ilcarbamico como antagonistas del receptor muscarinico m3 |
| WO2010007561A1 (en) | 2008-07-15 | 2010-01-21 | Pfizer Limited | Novel compounds active as muscarinic receptor antagonists |
| WO2010025202A1 (en) | 2008-08-29 | 2010-03-04 | Amgen Inc. | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF |
| WO2010025201A1 (en) | 2008-08-29 | 2010-03-04 | Amgen Inc. | Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases. |
| WO2010038428A1 (ja) | 2008-09-30 | 2010-04-08 | 武田薬品工業株式会社 | タキサン系抗がん剤の置き換え薬 |
| EP2206534A1 (de) | 2008-10-09 | 2010-07-14 | c-a-i-r biosciences GmbH | Dibenzocycloheptanonderivate und pharmazeutische Mittel, welche diese Verbindungen enthalten |
| US8497269B2 (en) | 2008-10-10 | 2013-07-30 | Amgen Inc. | Phthalazine compounds as p38 map kinase modulators and methods of use thereof |
| US8772481B2 (en) | 2008-10-10 | 2014-07-08 | Amgen Inc. | Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof |
| WO2010083246A1 (en) | 2009-01-15 | 2010-07-22 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| JP2012517405A (ja) | 2009-02-09 | 2012-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器及び胃腸の疾患の治療のための新規医薬組成物 |
| EP2396302A2 (en) | 2009-02-13 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides) |
| EP2396303A2 (en) | 2009-02-13 | 2011-12-21 | Vertex Pharmaceuticals Incorporated | Solid forms of 2-(2, 4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide |
| GB0902648D0 (en) | 2009-02-17 | 2009-04-01 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
| BRPI1005327A2 (pt) | 2009-02-17 | 2019-09-24 | Chiesi Farm Spa | derivados de triazolopiridina como inibidores de p38 map quinase |
| WO2010120963A1 (en) | 2009-04-16 | 2010-10-21 | Bristol-Myers Squibb Company | Tablet formulation for p38 inhibitor and method |
| US8513289B2 (en) | 2009-05-05 | 2013-08-20 | Merck Sharp & Dohme Corp. | P38 kinase inhibiting agents |
| US20120157500A1 (en) | 2009-08-24 | 2012-06-21 | Weikang Tao | Jak inhibition blocks rna interference associated toxicities |
| SG10201406763WA (en) | 2009-10-22 | 2014-11-27 | Genentech Inc | Modulation of axon degeneration |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| WO2011083387A1 (en) | 2010-01-07 | 2011-07-14 | Pfizer Limited | Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester |
| EA022360B1 (ru) | 2010-03-24 | 2015-12-30 | Онконова Терапьютикс, Инк. | Композиции и способы для профилактики и лечения ран |
| CA2792913C (en) | 2010-03-26 | 2020-01-21 | Onconova Therapeutics, Inc. | Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone |
| GB201009731D0 (en) | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
| JP5826261B2 (ja) | 2010-06-28 | 2015-12-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン |
| SG186871A1 (en) | 2010-07-05 | 2013-02-28 | Merck Patent Gmbh | Bipyridyl derivatives useful for the treatment of kinase - induced diseases |
| WO2012031057A1 (en) | 2010-09-01 | 2012-03-08 | Bristol-Myers Squibb Company | Bms- 582949 for the treatment of resistant rheumatic disease |
| RU2013129860A (ru) | 2010-11-29 | 2015-01-10 | Дженентек, Инк. | Способы выявления нейродегенеративных заболеваний или нарушений |
| TWI410425B (zh) | 2010-12-03 | 2013-10-01 | Lilly Co Eli | 唑并[5,4-b]吡啶-5-基化合物 |
| ES2542647T3 (es) | 2011-03-09 | 2015-08-07 | Merck Patent Gmbh | Derivados de pirido[2,3 b]pirazina y sus usos terapéuticos |
| CA2835707C (en) | 2011-05-09 | 2019-02-26 | Eip Pharma, Llc | Compositions and methods for treating alzheimer's disease |
| BR112013031493B1 (pt) | 2011-06-10 | 2022-04-19 | Chiesi Farmaceutici S.P.A | Composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto |
| EP2729146B1 (en) | 2011-07-08 | 2017-03-08 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for treatment of liver cancer |
| CA2850559C (en) | 2011-11-11 | 2016-11-29 | Eli Lilly And Company | Combination therapy for ovarian cancer |
| WO2013086002A1 (en) | 2011-12-05 | 2013-06-13 | Cellworks Research India Private Limited | Compositions, process of preparation of said compositions and method of treating cancer |
| SG11201402985VA (en) | 2011-12-09 | 2014-08-28 | Chiesi Farma Spa | Kinase inhibitors |
| MY167216A (en) | 2011-12-09 | 2018-08-14 | Chiesi Farm Spa | Kinase inhibitors |
| BR112014013178A2 (pt) | 2011-12-09 | 2017-06-13 | Chiesi Farm Spa | composto, composição farmacêutica e uso de um composto |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| DK2819998T3 (da) | 2012-03-01 | 2022-04-19 | Array Biopharma Inc | Krystallinske former af 1-(3-tert-butyl-1-P-tolyl-1H-pyrazol-5-yl)-3-(5-fluor-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)ureahydrochlorid |
| ES2605942T3 (es) | 2012-03-20 | 2017-03-17 | Mereo Biopharma 1 Limited | Uso de un derivado de pirazol en el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva crónica |
| JP6267193B2 (ja) | 2012-05-22 | 2018-01-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 置換ジピリジルアミン類及びそれらの使用 |
| CN104684546A (zh) * | 2012-06-07 | 2015-06-03 | 哈佛大学校长及研究员协会 | 用于药物靶向的纳米疗法 |
| US20150209337A1 (en) | 2012-07-17 | 2015-07-30 | Glaxosmithkline Llc | Nicotinamide derivate in the treatment of acute coronary syndrome |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| US9155747B2 (en) | 2012-09-13 | 2015-10-13 | Chiesi Farmaceutici S.P.A. | Isoxazolidine derivatives |
| EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
| EP2925323B1 (en) | 2012-11-30 | 2017-05-17 | F. Hoffmann-La Roche AG | An inhibitor of bruton's tyrosine kinase |
| US9370527B2 (en) | 2012-12-28 | 2016-06-21 | The Regents Of The University Of Michigan | Amelioration of intestinal fibrosis and treatment of Crohn's disease |
| JP6433922B2 (ja) | 2013-02-27 | 2018-12-05 | アレイ バイオファーマ、インコーポレイテッド | インダゾール誘導体の調製に使用するための中間体およびその調製方法 |
| EP2970190A1 (en) | 2013-03-14 | 2016-01-20 | Respivert Limited | Kinase inhibitors |
| GB201305714D0 (en) | 2013-03-28 | 2013-05-15 | Ucl Business Plc | Method |
| KR20150135328A (ko) * | 2013-04-01 | 2015-12-02 | 풀매트릭스 인코퍼레이티드 | 티오트로피움 건조 분말 |
| EP2981535B8 (en) | 2013-04-02 | 2021-03-10 | Oxular Acquisitions Limited | Urea derivatives useful as kinase inhibitors |
| WO2014181213A1 (en) | 2013-05-10 | 2014-11-13 | Pfizer Inc. | Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide |
| RU2015151886A (ru) | 2013-06-06 | 2017-06-08 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Ингибиторы киназ |
| EP3004087B1 (en) | 2013-06-06 | 2017-08-09 | CHIESI FARMACEUTICI S.p.A. | Derivatives of [1,2,4]triazolo[4,3-a]pyridine as p38-map kinase inhibitors |
| KR20160015221A (ko) | 2013-06-06 | 2016-02-12 | 키에시 파르마슈티시 엣스. 피. 에이. | 키나아제 억제제 |
| CA2917277A1 (en) | 2013-07-10 | 2015-01-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Losmapimod for use in treating glomerular disease |
| US20160151380A1 (en) | 2013-07-12 | 2016-06-02 | The Regents Of The University Of California | Therapies for diseases caused by arthropod-borne parasites |
| US9814728B2 (en) * | 2013-09-20 | 2017-11-14 | Saint Louis University | Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi) |
| US10813920B2 (en) * | 2013-11-14 | 2020-10-27 | The Doshisha | Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage |
| JP6514703B2 (ja) | 2013-12-20 | 2019-05-15 | トピバート ファーマ リミテッド | キナーゼインヒビターとして有用な尿素誘導体 |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| ES2774249T3 (es) | 2014-02-14 | 2020-07-20 | Respivert Ltd | Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios |
| US20170066741A1 (en) | 2014-02-19 | 2017-03-09 | H. Lundbeck A/S | 2-Amino-3,5,5-Trifluoro-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treatment of Alzheimer's Disease |
| WO2015191986A1 (en) | 2014-06-13 | 2015-12-17 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| EP3154588A1 (en) | 2014-06-13 | 2017-04-19 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| US9579322B2 (en) | 2014-07-09 | 2017-02-28 | Eip Pharma, Llc | Methods for treating neurologic disorders |
| EP3201189A1 (en) | 2014-10-01 | 2017-08-09 | Respivert Limited | N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors |
| MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| WO2016049677A1 (en) | 2014-10-03 | 2016-04-07 | The Walter And Eliza Hall Institute Of Medical Research | Method of treating cancer |
| WO2016066687A1 (en) | 2014-10-30 | 2016-05-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Losmapimod for treating copd |
| WO2016114655A1 (en) * | 2015-01-12 | 2016-07-21 | Ry Pharma B.V. | Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation |
| US10538763B2 (en) * | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
| WO2016124793A1 (en) | 2015-02-06 | 2016-08-11 | Association Institut De Myologie | Treatment of facioscapulohumeral dystrophy |
| TWI703138B (zh) | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β2腎上腺素受體促效劑活性之化合物 |
| JP6701225B2 (ja) | 2015-03-09 | 2020-05-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 三環式dlk阻害剤及びその使用 |
| WO2016154329A2 (en) * | 2015-03-24 | 2016-09-29 | The Trustees Of The University Of Pennsylvania | P38 map kinase inhibitors for treating friedreich's ataxia |
| JP2016193870A (ja) | 2015-04-01 | 2016-11-17 | 国立大学法人広島大学 | 慢性骨髄性白血病治療剤 |
| US9968604B2 (en) | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
| ES2993462T3 (en) * | 2015-05-20 | 2024-12-30 | Sumitomo Pharma Co Ltd | Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide |
| EP3302442B1 (en) * | 2015-06-03 | 2024-10-16 | Triastek, Inc. | Dosage forms and use thereof |
| WO2016198698A2 (en) | 2015-06-12 | 2016-12-15 | Cnic Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | P38 inhibitors for the treatment and prophylaxis of liver cancer |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| US9427439B1 (en) | 2015-10-26 | 2016-08-30 | Eip Pharma, Llc | Methods and compositions for recovery from stroke |
| CN108348524A (zh) | 2015-10-26 | 2018-07-31 | 爱普制药有限责任公司 | 用于从中风恢复的方法和组合物 |
| WO2017093208A1 (en) | 2015-12-03 | 2017-06-08 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| AR107163A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | Inhibidores de quinasa |
| EP3381472A4 (en) | 2015-12-24 | 2019-07-31 | The Doshisha | MEDICINAL PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISTURBANCES CAUSED BY TGF SIGNALS AND USE THEREOF |
| US20190125735A1 (en) | 2015-12-29 | 2019-05-02 | Board Of Regents, The University Of Texas System | Inhibition of p38 mapk for the treatment of cancer |
| CN109069516A (zh) * | 2016-02-01 | 2018-12-21 | 哈佛学院校长同事会 | 用于小鼠卫星细胞增殖的小分子 |
| WO2017134053A1 (en) | 2016-02-04 | 2017-08-10 | Chiesi Farmaceutici S.P.A. | Pyrazole derivatives as phosphoinositide 3-kinases inhibitors |
| CN115105601A (zh) | 2016-06-08 | 2022-09-27 | 投资支持有限公司 | 用于治疗癌症的药物组合 |
| GB201611712D0 (en) | 2016-07-02 | 2016-08-17 | Hvivo Services Ltd | Methods and compounds for the treatment or prevention of severe or persistent influenza |
| WO2018148797A1 (en) | 2017-02-15 | 2018-08-23 | The University Of Melbourne | A method of treatment |
| ES2927715T3 (es) | 2017-10-05 | 2022-11-10 | Fulcrum Therapeutics Inc | Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD |
| US20200297696A1 (en) | 2017-11-21 | 2020-09-24 | Saint Louis University | P38 inhibitors for the treatment of fshd |
| CA3119781A1 (en) | 2018-11-20 | 2020-05-28 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease |
| US12636290B2 (en) * | 2018-12-20 | 2026-05-26 | Saint Louis University | BET inhibitors for modulating DUX4 expression in FSHD |
| IL323757A (en) | 2019-03-15 | 2025-12-01 | Fulcrum Therapeutics Inc | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| AU2021342155A1 (en) * | 2020-09-11 | 2023-04-13 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use |
-
2018
- 2018-10-05 ES ES18792812T patent/ES2927715T3/es active Active
- 2018-10-05 KR KR1020207012671A patent/KR20200067170A/ko active Pending
- 2018-10-05 WO PCT/US2018/054642 patent/WO2019071147A1/en not_active Ceased
- 2018-10-05 BR BR112020006677-0A patent/BR112020006677A2/pt not_active Application Discontinuation
- 2018-10-05 AU AU2018346709A patent/AU2018346709A1/en not_active Abandoned
- 2018-10-05 CA CA3078232A patent/CA3078232A1/en active Pending
- 2018-10-05 PH PH1/2020/550215A patent/PH12020550215B1/en unknown
- 2018-10-05 HU HUE18792812A patent/HUE060024T2/hu unknown
- 2018-10-05 WO PCT/US2018/054638 patent/WO2019071144A1/en not_active Ceased
- 2018-10-05 CN CN201880078570.9A patent/CN111601593B/zh active Active
- 2018-10-05 PT PT187928122T patent/PT3691620T/pt unknown
- 2018-10-05 CN CN202210309230.0A patent/CN114748622B/zh active Active
- 2018-10-05 EP EP22186319.4A patent/EP4159212A1/en not_active Withdrawn
- 2018-10-05 TW TW107135292A patent/TWI793191B/zh not_active IP Right Cessation
- 2018-10-05 DK DK18792812.2T patent/DK3691620T3/da active
- 2018-10-05 SG SG10202110259Q patent/SG10202110259QA/en unknown
- 2018-10-05 LT LTEPPCT/US2018/054642T patent/LT3691620T/lt unknown
- 2018-10-05 SG SG11202003035SA patent/SG11202003035SA/en unknown
- 2018-10-05 AU AU2018346712A patent/AU2018346712B2/en active Active
- 2018-10-05 CN CN202210309271.XA patent/CN114732910B/zh active Active
- 2018-10-05 CN CN201880078497.5A patent/CN111868237A/zh active Pending
- 2018-10-05 NZ NZ762856A patent/NZ762856A/en unknown
- 2018-10-05 RS RS20220874A patent/RS63581B1/sr unknown
- 2018-10-05 JP JP2020520036A patent/JP2021501130A/ja active Pending
- 2018-10-05 JP JP2020519982A patent/JP7012152B2/ja active Active
- 2018-10-05 KR KR1020207012461A patent/KR20200066655A/ko not_active Ceased
- 2018-10-05 MX MX2020003594A patent/MX381225B/es unknown
- 2018-10-05 CA CA3128468A patent/CA3128468A1/en active Pending
- 2018-10-05 EP EP18792812.2A patent/EP3691620B1/en active Active
- 2018-10-05 CA CA3127373A patent/CA3127373A1/en active Pending
- 2018-10-05 BR BR112020006169-7A patent/BR112020006169A2/pt unknown
- 2018-10-05 HR HRP20221196TT patent/HRP20221196T1/hr unknown
- 2018-10-05 MX MX2020003961A patent/MX2020003961A/es unknown
- 2018-10-05 PL PL18792812.2T patent/PL3691620T3/pl unknown
- 2018-10-05 US US16/753,664 patent/US11479770B2/en active Active
- 2018-10-05 UY UY0001037918A patent/UY37918A/es not_active Application Discontinuation
- 2018-10-05 EP EP18797227.8A patent/EP3692144A1/en not_active Withdrawn
- 2018-10-05 CA CA3077499A patent/CA3077499C/en active Active
- 2018-10-19 US US16/166,031 patent/US10342786B2/en active Active
- 2018-11-19 US US16/195,361 patent/US10537560B2/en active Active
-
2020
- 2020-01-21 US US16/748,217 patent/US11291659B2/en active Active
- 2020-03-25 IL IL273589A patent/IL273589B/en active IP Right Grant
- 2020-03-27 IL IL273657A patent/IL273657A/en unknown
- 2020-04-01 PH PH12020550195A patent/PH12020550195A1/en unknown
- 2020-04-03 CL CL2020000913A patent/CL2020000913A1/es unknown
- 2020-04-03 CL CL2020000911A patent/CL2020000911A1/es unknown
- 2020-04-29 CO CONC2020/0005351A patent/CO2020005351A2/es unknown
- 2020-04-30 CO CONC2020/0005417A patent/CO2020005417A2/es unknown
- 2020-05-04 EC ECSENADI202024210A patent/ECSP20024210A/es unknown
- 2020-05-04 ZA ZA2020/02315A patent/ZA202002315B/en unknown
- 2020-06-24 CL CL2020001719A patent/CL2020001719A1/es unknown
-
2021
- 2021-11-12 US US17/525,394 patent/US20220133704A1/en not_active Abandoned
- 2021-12-13 JP JP2021201984A patent/JP2022031915A/ja active Pending
-
2022
- 2022-05-11 US US17/741,993 patent/US20220282254A1/en not_active Abandoned
- 2022-09-20 US US17/949,048 patent/US20230257743A1/en not_active Abandoned
-
2023
- 2023-05-16 JP JP2023081029A patent/JP2023113691A/ja active Pending
- 2023-10-02 JP JP2023171577A patent/JP2024012295A/ja active Pending
-
2025
- 2025-06-17 AU AU2025204512A patent/AU2025204512A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230257743A1 (en) | Use of p38 inhibitors to reduce expression of dux4 | |
| US11806555B2 (en) | Methods for treating hair loss disorders | |
| US10407734B2 (en) | Compositions and methods of using transposons | |
| US9662314B2 (en) | Compounds and methods for the treatment of muscular disease, and related screening methods | |
| US20130156795A1 (en) | Methods for inhibition of cell proliferation, synergistic transcription modules and uses thereof | |
| EP2971120B1 (en) | Transposon activation during aging and neuronal decline | |
| JP2022512773A (ja) | 加齢関連クローン性造血およびそれに関係する疾患の予防 | |
| TW202539748A (zh) | 辨識有可能受益於以端粒酶抑制劑治療之患者的方法 | |
| WO2014039696A2 (en) | Transposable elements, tdp-43, and neurodegenerative disorders | |
| Ferreira et al. | The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies | |
| US20250346864A1 (en) | Modulation of satellite cell polarity and asymmetric cell division | |
| US20260125683A1 (en) | Treatment of cancers having a drug-resistant mesenchymal cell state | |
| JP5995163B2 (ja) | Mycn増幅型疾患のための分子標的及びその利用 | |
| Kanthasamy | Minhong Huang, Dan Lou2, Zhibin Wang2, Huajun Jin1, Vellareddy Anantharam1, Arthi | |
| HK40107707A (en) | Compositions and methods for treating alzheimer's disease | |
| EA046703B1 (ru) | Ингибиторы киназы р38 снижают экспрессию dux4 и последующих генов для лечения fshd | |
| HK40036489A (en) | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd | |
| HK40036489B (en) | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220914 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250328 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250328 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250716 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250926 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250926 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251117 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260708 |